Despite substantial advancement in targeted biological inhibitors used for controlling psoriasis, such as tumor necrosis factor α (TNF-α) inhibitors (etanercept, adalimumab, certolizumab, and infliximab), interleukin (IL)-12 and IL-13 inhibitors (ustekinumab), IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab, and brodalumab), and inhibitors of the p19 subunit of IL-23 (guselkumab, tildrakizumab, risankizumab, and mirikizumab) [8], long-term disease modification and cure remain significant medical issues [9]. This evidence concerns the gene TNF and psoriasis.